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Abstract
Background: Time of starting antiretroviral therapy (ART) after diagnosis of specific AIDS-defining event (ADE) is a crucial
aspect. Objectives of this study were to evaluate if in patients diagnosed with ADE the time to ART initiation may vary
according to year of diagnosis and type of ADE.
Methods: All HIV+ persons diagnosed with an ADE over the 6 months prior to or after enrolment in the Icona Foundation
study cohort and while ART-naive were grouped according to type of diagnosis: Those with ADE requiring medications
interacting with ART [group A], those with ADE treatable only with ART [B] and other ADE [C]. Survival analysis by Kaplan-
Meier was used to estimate the percentage of people starting ART, overall and after stratification for calendar period and
ADE group. Multivariable Cox regression model was used to investigate association between calendar year of specific ADE
and time to ART initiation.
Results: 720 persons with first ADE were observed over 1996–2013 (group A, n = 171; B, n = 115; C, n = 434). By 30 days from
diagnosis, 27% (95% CI: 22–32) of those diagnosed in 1996–2000 had started ART vs. 32% (95% CI: 24–40) in 2001–2008 and
43% (95% CI: 33–47) after 2008 (log-rank p = 0.001). The proportion of patients starting ART by 30 days was 13% (95% CI 7–
19), 40% (95% CI: 30–50) and 38% (95% CI 33–43) in ADE groups A, B and C (log-rank p = 0.0001). After adjustment for
potential confounders, people diagnosed after 2008 remained at increased probability of starting ART more promptly than
those diagnosed in 1996–1999 (AHR 1.72 (95% CI 1.16–2.56).
Conclusions: In our ‘‘real-life’’ setting, the time from ADE to ART initiation was significantly shorter in people diagnosed in
more recent years, although perhaps less prompt than expected.
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Introduction
A large proportion of HIV-infected people still present for care
with low CD4 cell count or with an AIDS-defining event (ADE) at
first diagnosis of HIV infection [1]. This represents a population
with higher probability of clinical progression and death [2] and
lower chances of immunological recovery [3]. The optimal timing
of starting ART for people presenting with ADE has been debated
for a long time. The results of the AIDS Clinical Trials Group
(ACTG) protocol 5164 showed that starting antiretroviral therapy
within the first 30 days after a diagnosis of opportunistic infections
(OI) other than tuberculosis reduces AIDS progression and death
by 50% [4] compared to delayed initiation. Moreover, a
subsequent analysis of the same trial demonstrated that early
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initiation is also a cost-effective approach [5]. Following the
presentation of ACTG findings, a number of national and
international guidelines have been modified accordingly. In
particular, currently the Italian guidelines state that people with
different ADE (except for meningeal tuberculosis and criptococ-
cosis) should start ART within 30 days from ADE diagnosis [6–8].
Nevertheless, the extent to which clinicians in ‘real life’ strictly
follow these guidelines remains unexplored. Preliminary results on
people diagnosed with Pneumocystis jiroveci pneumonia (Pcp)
demonstrated that it may be feasible to treat these patients very
early [9]. Nevertheless, the risk of overlapping toxicities, as well as
pharmacokinetics/pharmacodinamics interactions between anti-
retrovirals and specific treatment of OI, and the high pill burden
with subsequent risk of poor adherence may all represent factors
limiting the strict implementation of these new recommendations
[10–13]. In order to evaluate the possible impact of changes in
Italian guidelines following the dissemination of the results of trials
such as ACTG 5164, we analysed temporal changes of the time
from a first diagnosis of ADE to the time of starting antiretroviral
treatement (ART) in patients of the Icona Foundation Study
cohort who were diagnosed with AIDS when ART-naive.
Methods
Study population
All HIV-1 infected patients of the ICONA Foundation Study
who were diagnosed with AIDS while ART-naı¨ve regardless of
time of enrolment in the cohort and of their CD4 cell count were
considered for this analysis (eligible patients). ICONA Foundation
Study is an observational cohort of HIV-infected individuals who
are antiretroviral naı¨ve at the time of enrolment [14]. This cohort
was set up in January, 1997 and to date consists of more than
10,000 patients from 50 infectious disease units in Italy. Initiation
and discontinuation dates of each antiretroviral drug, HIV-viral
load and CD4 cell count at each clinical visit (every 4–6 months on
an average) were recorded for each enrolled patient. AIDS-
defining diseases are recorded in the database at the date that this
diagnosis is confirmed or presumptive according to Centers for
Disease Control and Prevention (CDC) criteria [15]. Of the
eligible patients, only individuals who were diagnosed over the 6
months prior to enrolment in the cohort or those diagnosed under
prospective follow-up in the cohort and while still ART-naı¨ve were
included in this analysis (Flow Chart, Figure 1).
Ethics statements
All individuals signed an informed consent prior to enrollment
and the study was approved by the Ethics Committee of each
participating institution that are listed in the Aknowledgments.
Statistical analysis
Patients included were classified in 3 groups according to the
type of AIDS diagnosis observed using a ‘in house’ algorithm for
classification. Specifically, the groups were defined ‘a priori’ on the
basis of the expected probability of prompt initiation of ART:
Group A) OIs treated with drugs that may have interaction with
ART such as for example rifamicins and antineoplastic drugs with
both NNRTI and PIs: tuberculosis (TB), atypical mycobacteriosis,
non-Hodgkin lymphoma (NHL); Group B) ADE treatable mainly
by ART: progressive multifocal leucoencephalopathy (PML),
Kaposi’s sarcoma (KS), wasting syndrome, cryptosporidiasis,;
and Group C) all other ADEs (i.e. Pcp, Cytomegalovirus retinitis,
toxoplasmic encephalitis, cervical cancer, criptococcosis, esopha-
geal candidiasis). The expected timing of starting ART was the
slowest for group A diseases, prompt for group B and intermediate
for group C.
Notwithstanding specific treatment for some conditions includ-
ed in group C may potentially interact with ART but these
interactions have not been demonstrated at a pharmacokinetic
level.
The inclusion of Kaposi sarcoma in group B might be arbitrary,
nevertheless, even though international treatment guidelines
recommend the use of polichemotherapy (PCT) together with
ART for people with moderate to severe disease ($T1), in clinical
practice, starting ART represents the most rapid curative
intervention for any patient presenting with KS.
Further, different indications for timing of starting ART for
NHL and TB (both included in group A) are reported in updated
guidelines and could have influenced the decision of clinicians;
however, considering that the calendar periods of observation are
very different in the studied population, we decided to use the
potential risk of drug-drug interaction as a more homogeneous ‘‘a
Figure 1. Flow diagram showing the original population of people diagnosed with AIDS while ART-naive, patients definitively
considered for the analysis, and reasons for exclusion.
doi:10.1371/journal.pone.0089861.g001
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Table 1. Characteristics of patients according to time period of AIDS diagnosis.
Characteristics at AIDS diagnosis 1996–2000 2001–2008 2009+ p-value* Total
N=332 N=172 N=216 N=720
Age, years
Median (IQR) 37 (32, 43) 40 (34, 47) 39 (34, 47) ,.001 38 (33, 45)
Gender, n(%)
Female 86 (25.9%) 58 (33.7%) 58 (26.9%) 0.161 202 (28.1%)
Nation of birth, n(%)
Italian 296 (89.2%) 138 (80.2%) 142 (65.7%) ,.001 576 (80.0%)
Mode of HIV Transmission, n(%) ,.001
IDU 123 (37.0%) 26 (15.1%) 18 (8.3%) 167 (23.2%)
Homosexual contacts 72 (21.7%) 38 (22.1%) 52 (24.1%) 162 (22.5%)
Heterosexual contacts 112 (33.7%) 89 (51.7%) 123 (56.9%) 324 (45.0%)
Other/Unknown 25 (7.5%) 19 (11.0%) 23 (10.6%) 67 (9.3%)
Calendar year of AIDS diagnosis
Median (range) 1998 (1996, 2000) 2004 (2001, 2008) 2011 (2009, 2013) ,.001 2002 (1996, 2013)
HBsAg, n(%) ,.001
Negative 283 (85.2%) 147 (85.5%) 154 (71.3%) 584 (81.1%)
Positive 6 (1.8%) 4 (2.3%) 2 (0.9%) 12 (1.7%)
Not tested 43 (13.0%) 21 (12.2%) 60 (27.8%) 124 (17.2%)
HCVAb, n(%) ,.001
Negative 164 (49.4%) 112 (65.1%) 136 (63.0%) 412 (57.2%)
Positive 136 (41.0%) 37 (21.5%) 21 (9.7%) 194 (26.9%)
Not tested 32 (9.6%) 23 (13.4%) 59 (27.3%) 114 (15.8%)
CD4 count, cells/mmc
Median (IQR) 60 (24, 150) 57 (24, 221) 51 (17, 165) 0.689 56 (22, 158)
Viral load, log10 copies/mL
Median (IQR) 5.31 (4.80, 5.77) 5.14 (4.25, 5.56) 5.30 (4.67, 5.71) 0.065 5.27 (4.66, 5.70)
CD8 count, cells/mmc
Median (IQR) 494 (285, 791) 512 (311, 917) 580 (272, 1052) 0.603 526 (292, 889)
CD4/CD8 ratio, cells/mmc
Median (IQR) 0.12 (0.06, 0.22) 0.15 (0.07, 0.34) 0.14 (0.05, 0.30) 0.533 0.13 (0.06, 0.27)
ADE group, n(%) 0.676
Group A 86 (25.9%) 35 (20.3%) 50 (23.1%) 171 (23.8%)
Group B 49 (14.8%) 29 (16.9%) 37 (17.1%) 115 (16.0%)
Group C 197 (59.3%) 108 (62.8%) 129 (59.7%) 434 (60.3%)
Haemglobin, g/dL
Median (IQR) 11 (10, 13) 11 (10, 13) 12 (10, 13) 0.682 11 (10, 13)
White Blood Cell, cells/mmc
Median (IQR) 4000 (2980, 6200) 4700 (3500, 6200) 4570 (3155, 6665) 0.161 4390 (3100, 6230)
ALT, IU/L
Median (IQR) 31 (22, 51) 36 (21, 52) 34 (21, 58) 0.472 32 (21, 53)
AST, IU/L
Median (IQR) 35 (23, 56) 33 (24, 50) 36 (25, 57) 0.845 35 (24, 56)
eGFR, 100 mls/min/1.73 m2
Median (IQR) 88.94 (70.60, 92.93) 107.7 (87.27, 123.5) 105.3 (91.11, 128.7) 0.037 104.4 (87.27, 124.5)
Reason for enrolment, n(%) ,.001
No indications for ART 23 (6.9%) 21 (12.2%) 5 (2.4%) 49 (6.9%)
Patients decision 65 (19.6%) 7 (4.1%) 10 (4.9%) 82 (11.5%)
Contraindications 4 (1.2%) 1 (0.6%) 2 (1.0%) 7 (1.0%)
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priori’’ criterion used by clinicians to decide either to start ART or
not.
In case of multiple diagnoses, clinicians are asked to rank the
illness in order of disease severity, and the most severe condition
was used for classification in the analysis (data not shown).
ART was defined as a regimen of $1 drug belonging to one of
the 3 major historical drug classes (NRTI, NNRTI and PI).
Calendar periods of AIDS diagnosis were grouped as 1996–
2000, 2001–2008, and 2009+, the earliest period reflecting the
years of old generation ART regimens typically with a heavy pill
burden and lower tolerability, the latter period reflecting the years
after the introduction of modern regimens and following the first
presentation of the results of the ACTG 5164 trial at an
International Conference [16].
Standard survival analysis by Kaplan-Meier was used to
estimate the cumulative percentage of people starting ART from
the date of AIDS diagnosis (overall and after stratification for both
calendar periods and type of ADEs).
All KM plots have been truncated at 30 days. The threshold of
30 days were based on current treatment guidelines as well as
assumptions. Thirty days is the maximum length of time whitin
which is recommended to start ART after a diagnosis of all
opportunistic conditions, except for tuberculosis and criptococco-
sis.
Multivariable Cox regression model was used to investigate the
association between calendar periods of diagnosis and type of ADE
with time to ART initiation after controlling for age, gender,
nation of birth, HIV transmission route, hepatitis co-infection
status, reason for enrolment in the cohort, CD4 count at diagnosis
and number of concomitant ADE (single vs. multiple). All
demographics as well as laboratory markers that were associated
in univariable analysis with a p-value = 0.15 were included in the
multivariable model with the exception of CD8 and white blood
cell counts which were collinear with CD4 counts.
Results
Baseline patients characteristics
A total of 720 individuals diagnosed with AIDS over the 6
months prior to enrolment in the cohort or under prospective
follow-up while still ART-naı¨ve were included in this analysis. In
included patients, the mean time between HIV and AIDS
diagnosis was 32 (SD = 56) months and between enrolment and
AIDS diagnosis was 3 (SD = 15) months. Selected characteristics of
the study population overall and according to periods of AIDS
diagnosis are shown in Table 1. People who were diagnosed with
AIDS in 2009 or after were less likely to be Italian born (p,0.001),
intravenous drug users (p,0.001) and co-infected with HCV
(p,0.001) than those diagnosed in previous years (Table 1).
Of the 720 individuals studied, 171 (24%) had a main diagnosis
of group A, 115 (16%) of group B and the remaining 434 (60%) of
group C. 120 patients (17%) were diagnosed with multiple ADE.
Patients in group B were older (p,0.001), more likely to be of
Italian origin (p,0.001), whereas patients in Group A had lower
CD4 cell count at the time of AIDS diagnosis (both p,0.001) than
patients with OIs classified in other groups (Table S1).
Overall, considering only the major diagnosis for each
individual in those with multiple ADE according to the criterion
of severity described in the Methods, the prevalence of specific
opportunistic conditions were 32% for Pneumocystis jrovecii
pneumonia (Pcp, n = 231), 16% for tuberculosis (TB, n = 115),
12% for esophageal candidiasis (n = 84), 5.4% for CMV disease
(n = 39), 7% for Kaposi sarcoma (n = 50), 6.3% for toxoplasma
encephalitis (n = 45), 7% for wasting syndrome (n = 23); 5.4% for
non Hodgkin Lymphoma (NHL, n = 39), all other conditions were
observed at a frequency less than 3%. We then assessed trends
over time for specific diagnosis with at least 30 patients being
diagnosed. A trend for decreasing prevalence was observed for
esophageal candidiasis (46%, 19%, 34% respectively, in the 3
periods), Pcp (45%, 25%, 29%) and TB (54%, 18%, 26%). In
contrast, a stable prevalence was seen for CMV (23%, 36% and
41%) and KS (32%, 24% and 44%) and for NHL (31%, 31%,
38%).
Analysis of time to starting cART according to different
periods and groups of ADEs
Overall, 518 people (72%) started ART over follow-up after the
AIDS diagnosis; by 30 days from the AIDS diagnosis 33% started
ART (95% CI: 29–37).
Out of 518 persons starting ART, 94 persons (19%) started a
regimen containing a 2NRTI+NNRTI, 167 (32%) a 2NRTI+PI
without ritonavir boosting, 170 (33%) a 2NRTI+PI/r and 87
(17%) other types of regimen (these include 61 people starting less
than 3 drugs-53 with 2NRTI alone).
Figure 2 shows the Kaplan Meier estimates of the cumulative
probability of starting ART, according to the calendar period of
starting ART (Figure 2a) and to group of ADEs (Figure 2b). The
Kaplan Meier estimate of the median time to ART initiation was
58 days [95% CI: 48–70] for patients diagnosed in the period
1996–1999, 45 days [95%CI: 34–51] for those diagnosed during
Table 1. Cont.
Characteristics at AIDS diagnosis 1996–2000 2001–2008 2009+ p-value* Total
N=332 N=172 N=216 N=720
Recent HIV diagnosis 167 (50.3%) 123 (71.5%) 163 (79.1%) 453 (63.8%)
Recent access to care 60 (18.1%) 16 (9.3%) 22 (10.7%) 98 (13.8%)
Physician decision 13 (3.9%) 3 (1.7%) 0 (0.0%) 16 (2.3%)
Unknown 0 (0.0%) 1 (0.6%) 4 (1.9%) 5 (0.7%)
Time from enrolment to ADE, days
Median (range) 0 (0, 1243) 0 (0, 3685) 0 (0, 4358) ,.001 0 (0, 4358)
Calendar year of HIV diagnosis
Median (IQR) 1997 (1991, 1998) 2003 (2000, 2005) 2011 (2010, 2012) ,.001 2000 (1997, 2009)
*Chi-square or Wilcoxon test as appropriate.
doi:10.1371/journal.pone.0089861.t001
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2000–2008, and 38 days [95%CI: 33–48] for those with a
diagnosis of AIDS in/after 2009. The proportions of people
starting ART by 30 days in these same groups were 27% (95%
CI:22–32) of those diagnosed in 1996–2000, 32% (95% CI:24–40)
of those in 2001–2008 and 43% (95% CI:33–47) of those in/after
2009 (log-rank p = 0.001, Figure 2a).
Patients in group A started ART after a median time of 116
days [95%CI 82–148], those in group B after a median of 35 days
[95%CI 30–49] and those in group C after 38 days [95%CI 35–
41, log-rank p = 0.0002, Figure 2b). The proportion of patients
starting ART by 30 days was 13% (95% CI 7–19), 40% (95% CI:
30–50) and 38% (95% CI 33–43) in ADE groups A, B and C,
respectively. After concomitantly stratifying for both these
variables, people belonging to group B diagnosed in or after
2009 had the highest overall probability of starting ART by 30
days (51%; 95%CI: 33–69) (Figure S1, data not shown). Of note,
the Kaplan-Meier estimate of the median time to starting ART in
the whole Icona cohort (11,303 individuals enrolled) is much
longer, at 157 months (95% CI:139–173).
After adjusting for a number of potential confounding factors
listed in the Methods, people diagnosed in 2009 or after, remained
at significantly increased probability of starting ART more
promptly than those who were diagnosed in 1996–1999: adjusted
HR (AHR) 1.72 (95% CI 1.16–2.56; p = 0.007). The strongest
calendar year effect seemed to have occurred for diagnoses
belonging to group A (AHR 3.61; 95%CI 1.48–8.77; p = 0.005)
(Table 2a).
Moreover, after controlling for potential confounders, time to
ART initiation was shorter in people belonging to group B (ARH
1.63, 95% CI:1.05–2.53; p = 0.02) compared to patients in group
A. The difference in time to start of ART between groups B and A
was consistent across calendar periods. (p-value for interaction
p = 0.19, Table 3).
Analysis of other predictors of starting ART
We identified other factors that were associated with the time of
ART initiation independent of calendar year and type of AIDS
diagnosis from fitting a Cox regression analysis (Table 4). People
born in Italy (vs. non Italian-born ARH = 1.83, 95% CI:1.21–
2.78) those with lower CD4 cell count at the time of their ADE
diagnosis (per 100 cells/mm3 lower AHR = 1.22 [95%CI 1.11–
1.34] and people who were enrolled in the cohort because recently
discovered to be HIV-infected (vs. those with no indications for
starting ART at enrolment, ARH = 1.86, 95% CI:1.17–2.93) were
Figure 2. Kaplan-Meier estimates of the cumulative proportion of patients starting ART by 30 days from ADE diagnosis, according
to period of starting ART (a) and group of ADEs (b).
doi:10.1371/journal.pone.0089861.g002
Table 2. Relative Hazards (RH) of starting ART from fitting a Cox regression analysis, according to calendar periods and stratified
by type of ADE.
Crude and adjusted relative hazards of ART initiation




2000–2008 1.19 (0.96, 1.48) 0.104 0.92 (0.67, 1.26) 0.610




2000–2008 1.09 (0.66, 1.81) 0.726 1.24 (0.59, 2.61) 0.578




2000–2008 0.95 (0.55, 1.65) 0.851 0.39 (0.13, 1.16) 0.090




2000–2008 1.21 (0.93, 1.57) 0.156 0.89 (0.58, 1.39) 0.619
2009+ 1.26 (0.96, 1.66) 0.095 1.32 (0.74, 2.37) 0.342
*adjusted for age, gender, nation of birth, mode of HIV transmission,hepatitis co-infection status, type of AIDS diagnosis-all patients model only-,reason for enrolment in
Icona, CD4 count and viral load at diagnosis, number of concomitant AIDS diagnoses
amycobacteriosis, tubercolosis, Non-Hodgkin lymphomas
bisosporidiosis, criptosporidiosis, PML, Kaposi sarcoma andAIDS dementia complex
call other ADE
doi:10.1371/journal.pone.0089861.t002
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significantly more likely to start ART. Interestingly, viral load at
the time of AIDS diagnosis was not independently associated with
the probability of starting ART.
Description of people not starting ART. Two hundred
and two patients were still off-ART. Of these 8 had died and the
remaining 194 had not commenced ART at the time that they
were last seen alive (Figure 1). The reasons for not starting ART or
being censored are not collected in our database. However, for the
633 patients who were diagnosed before or at the time of
enrolment we have the reason for being ART-naı¨ve. The main
reasons were: recent seroconversion (68%), recent access to care
(14%) and patients’ reasons (10%). Overall, the distribution of
reasons for being ART-naive at enrolment was similar in people
who subsequently started ART or those who remained off-ART
(data not shown).
Assessment of missing data. Some of the variables in the
model were fitted as categorical and individuals with missing data
for these factors have been grouped separately as ‘value unknown’.
People with missing data for variables included as continuous (e.g.
CD4 count at the date of AIDS diagnosis) were, however,
excluded from the multivariable calculations. People included and
excluded (due to missing values of these variables) were statistically
different for some demographic characteristics but large differ-
ences were not observed (data not shown) with the exception of
year of diagnosis (more recent year of AIDS diagnosis in excluded
patients [2007 on average], compared to patients included in
multivariable model [2000]). People who were diagnosed with
HIV in more recent years were more likely to have missing data
for CD4 count or viral load at time of their AIDS diagnosis. This
could be due to the fact that data collection was modified
approximately in 2005 to collect only one historical value of these
markers at entry in the cohort (two values were instead recorded in
previous years).
Discussion
The results of our analysis show that in recent years Italian
clinicians tend to initiate ART more promptly than in the past
after a diagnosis of AIDS. Nevertheless, even in recent years the
overall probability of starting ART seems to remain low (43% by
30 days from the AIDS diagnosis) with a median time to ART
initiation of 21 days. Indeed, these estimates are considerably
lower than what has been suggested as optimal time of starting
ART on the basis of the results of the ACTG 5164 trial [4]. Even
in the subset of people who were diagnosed under prospective
follow-up in the cohort, the estimate remains low (38% instead of
33% by 30 days). Of note, however, our estimates refer to any
diagnosis of OI while in the trial 75% of patients had been
diagnosed with Pcp and cases of TB were excluded.
To our knowledge ours is the first analysis evaluating whether
there has been a change in the timing of ART initiation in clinical
practice over time in cART-naive patients presenting for care with
different AIDS-defining conditions.
Recently, Geng et al reported a 3-fold increase in the rate of
ART initiation and an increase in the probability of early ART
from 7% to 50% after the diffusion of ACTG 5164 findings in a
single clinical center in the USA uniquely in patients diagnosed
with Pcp [9].
In a retrospective European and Canadian multi-cohort study,
aimed to analyse the clinical progression of AIDS-presenter
patients, the proportion of patients starting ART by 30 days from
diagnosis was 50% when considered the overall study population,
ranging from 70% in people diagnosed with KS to 30% in those
with NHL, with wide variation in the time to initiation also
according to country of origin [2]. Of note, not all individuals
studied by us were AIDS presenters, 462/720 (64%) developed
AIDS after enrolment in the cohort.
There are a number of potential concerns and obstacles to the
early initiation of ART in patients presenting with opportunistic
conditions: the risk of immune reconstitution inflammatory
syndrome, the concern for poor adherence to multi-drug
treatment, for drug-drug interactions potentially leading to adverse
events or poor treatment responses, and the difficulties in taking or
tolerating oral medications for critically ill patients. All these
represent potential reasons for delaying antiretroviral treatment
and may partially explain our findings [17]. Indeed, people with
AIDS defining conditions for which ART represents the only
treatment option were treated earlier, whereas those whose
conditions were treatable with medications having potential
drug-drug interaction with antiretrovirals were treated later.
Although both current Italian and International guidelines
report a general agreement on the net benefit of a prompt start of
ART in people with AIDS, data evaluating the effect of early ART
on specific opportunistic conditions other than Pcp, TB and
cryptococcosis are very limited, and this could lead the clinicians
Table 3. Relative hazards (RH) of starting ART according with
groups of ADEs from fitting a Cox regression analysis and
stratified by calendar period.










Group Aa 1.00 1.00
Group Bb 2.18 (1.63, 2.90) ,.001 1.63 (1.05, 2.53) 0.028
Group Cc 2.04 (1.64, 2.55) ,.001 1.01 (0.71, 1.42) 0.962
1996–1999
Type of ADE
Group Aa 1.00 1.00
Group Bb 2.30 (1.52, 3.48) ,.001 1.91 (1.04, 3.52) 0.037
Group Cc 2.18 (1.60, 2.96) ,.001 1.22 (0.78, 1.91) 0.392
2000–2008
Type of ADE
Group Aa 1.00 1.00
Group Bb 2.03 (1.08, 3.84) 0.029 1.55 (0.55, 4.40) 0.408
Group Cc 2.42 (1.48, 3.97) ,.001 1.00 (0.40, 2.51) 0.998
2009+
Type of ADE
Group Aa 1.00 1.00
Group Bb 1.99 (1.18, 3.36) 0.010 5.37 (1.08, 26.81) 0.040
Group Cc 1.55 (1.01, 2.38) 0.047 1.95 (0.52, 7.39) 0.325
*adjusted for age, gender, nation of birth, mode of HIV transmission,hepatitis
co-infection status, calendar period-all patients model only-,reason for
enrolment in Icona, CD4 count and viral load at diagnosis, number of
concomitantAIDS diagnoses
amycobacteriosis, tubercolosis, Non-Hodgkin lymphomas
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Table 4. Other factors associated with the chance of starting ART - Relative hazards (RH) from fitting a Cox regression.
Crude and adjusted relative hazards of ART initiation
Crude RH (95% CI) p-value Adjusted* RH (95% CI) p-value
Age
per 10 year older 1.20 (1.09, 1.31) ,.001 0.97 (0.84, 1.12) 0.652
Gender, n(%)
Male 1.00 1.00
Female 0.86 (0.71, 1.04) 0.122 1.14 (0.83, 1.55) 0.422
Nation of birth, n(%)
Non Italian 1.00 1.00
Italian 1.50 (1.19, 1.90) ,.001 1.83 (1.21, 2.78) 0.004
Mode of HIV Transmission, n(%)
IDU 1.00 1.00
Homosexual contacts 1.36 (1.05, 1.75) 0.018 1.11 (0.69, 1.79) 0.664
Heterosexual contacts 1.49 (1.19, 1.87) ,.001 1.07 (0.65, 1.76) 0.797
Other/Unknown 1.47 (1.04, 2.07) 0.029 1.02 (0.55, 1.89) 0.956
Calendar Period
1996–1999 1.00 1.00
2000–2008 1.19 (0.96, 1.48) 0.104 0.92 (0.67, 1.26) 0.610
2009+ 1.51 (1.22, 1.86) ,.001 1.72 (1.16, 2.56) 0.007
Hepatitis B/C coinfection, n(%)
Negative 1.00 1.00
Positive 0.77 (0.63, 0.93) 0.008 1.01 (0.67, 1.53) 0.948
Not tested 0.73 (0.57, 0.94) 0.013 0.44 (0.27, 0.72) 0.001
CD4 count
per 100 cells/mmc lower 1.22 (1.15, 1.29) ,.001 1.22 (1.11, 1.34) ,.001
Viral load
per log10 copies/mL higher 1.37 (1.20, 1.57) ,.001 1.06 (0.90, 1.25) 0.501
CD8 count
per 100 cells/mmc higher 0.96 (0.94, 0.98) ,.001
ADE group, n(%)
Group A 1.00 1.00
Group B 2.18 (1.63, 2.90) ,.001 1.63 (1.05, 2.53) 0.028
Group C 2.04 (1.64, 2.55) ,.001 1.01 (0.71, 1.42) 0.962
Haemglobin
per 100 g/dL higher 0.63 (0.37, 1.07) 0.089
White Blood Cell
per 1000 cells/mmc higher 0.91 (0.86, 0.95) ,.001
ALT
per 100 IU/L higher 1.07 (0.86, 1.34) 0.524
AST
per 100 IU/L higher 1.06 (0.84, 1.34) 0.627
eGFR
per 50 100 mls/min/1.73 m2 higher 1.29 (0.91, 1.82) 0.147
Reason for enrolment, n(%)
No indications for ART 1.00 1.00
Patients decision 1.12 (0.77, 1.62) 0.564 0.63 (0.37, 1.09) 0.097
Contraindications 0.64 (0.23, 1.78) 0.396 0.19 (0.03, 1.43) 0.107
Recent HIV diagnosis 2.04 (1.51, 2.76) ,.001 1.86 (1.17, 2.93) 0.008
Recent access to care 1.45 (1.01, 2.08) 0.045 1.26 (0.77, 2.08) 0.361
Timing of ART after First AIDS-Defining Event
PLOS ONE | www.plosone.org 8 February 2014 | Volume 9 | Issue 2 | e89861
to hesitate in ART initiation in people diagnosed with less well-
studied conditions such as CMV disease or esophageal candidiasis
or toxoplasmosis.
In our study population, TB accounted for 14% of people with
AIDS. When we looked at people diagnosed with TB alone the
median time to starting ART was 142 days (95% CI: 97–190). Of
note, we found that the effect of calendar period was stronger in
group A (including TB) than in group C (including Pcp); this was
confirmed even after restricting the analysis to people with TB or
Pcp only (data not shown). This may represent an unexpected
result, because recommendation on earlier start of ART based on
the data of ACTG 5164 concerned more specifically Pcp rather
than TB. It can be speculated that other factors may have affected
a prompt initiation of ART in people with TB such as a more
extensive use of NNRTI in the recent years (with less concerns in
terms of drug-drug interactions), or a progressive increase of
awareness of findings of randomized clinical trials on TB [18–21].
In addition, immune reconstitution inflammatory syndrome (IRIS)
is often observed after starting treatment for specific disorders (i.e.,
TB, CMV, criptococcosis) and this might be another reason why
clinicians are less likely to promptly start ART in people with TB.
The opposite trend was seen for people diagnosed with
cryptococcal meningitis (less chance to initiate ART in recent
periods) this might be due to increasing evidence for a worst
survival in patients with this pathology starting ART earlier [21–
22].
Investigating the predictors of time to ART initiation, we found
that patients whose reason for enrolment in Icona was a recent
diagnosis of HIV infection, were more likely to be promptly started
on ART compared to patients who had no indication for initiating
ART. These are likely to be people who were diagnosed with HIV
when they presented with AIDS and it is conceivable that their
time to ART initiation is the shortest. Of note indication for
starting ART have also been modified in guidelines over time but
to a lower extent for people with already a diagnosis of AIDS.
Moreover, patients of non-Italian nationality tended to start
ART later than Italian patients. Some concerns regarding the
retention in care of migrant patients might explain the conserva-
tive approach of clinicians in starting ART in this subset of
patients.
Our analysis has several limitations.
First, although a severity criterion could be establish for the
classification of ADE, for a given pathology, we do not collect data
on the degree of severity or progression of the disease. For
example, it could be hypothesized that in case of greater severity,
requiring also more intensive care, ART was not started
immediately because patients were not able to take it. Moreover,
AIDS diagnoses are typically made using a presumptive diagnostic
criterion according to CDC guidelines. As a consequence people
may be started on ART after a presumptive and before a
confirmative diagnosis and excluded from the analysis as a result.
This may have led to selection bias as well as over-estimation of
the estimated time to start ART. However, only 88 of the 720
diagnoses (12%) analyzed here were made using a presumptive
diagnostic criterion.
Furthermore, we did not perform a survival analysis with
endpoint death so we do not know what the impact of such a
conservative approach may be on mortality in a real practice
setting. We are indeed planning to investigate the association
between the strategies of starting ART within 15 days vs. starting
within 30 days vs delaying for longer than 30 days or not start at
all and the risk of death using g-computation in a separate report
[23]. Patients with missing data have been excluded from the
multivariable Cox regression analysis. However, included and
excluded patients were similar for the other measured character-
istics and therefore selection bias is unlikely. There was a large
difference in calendar year of diagnosis likely to be due to a change
in modality of data collection over time which is unrelated to time
to ART initiation.
In conclusion, in a real life setting of patients seen for care in
Italy, we show that the time from AIDS diagnosis to ART
initiation was significantly shorter in more recent years, even
though still considerably longer than what has been reported as
beneficial on survival in AIDS patients. Reasons for that could be
a delay in the implementation of guidelines in clinical practice, but
could also be due to real difficulties in treating these patients
concomitantly for opportunistic conditions and for HIV itself.
Similar prospective studies with data collection enrichment are
warranted to explore in details the specific barriers to ART
initiation in patients presenting with ADE.
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